This may represent a critical element for surveillance strategies for gastric cancer. “
“This review summarizes important studies regarding Helicobacter

pylori therapy published from April 2012 up to March 2013. To begin with, the updated European Consensus Guidelines were published last year, highlighting the role of bismuth and nonbismuth quadruple regimen as first-line treatments. Cure rates for standard triple therapy remain acceptable in quite a few settings nowadays, and some reports on innovative triple therapies look promising. One study evaluating bismuth quadruple therapy as first-line therapy was reported. Regarding nonbismuth quadruple regimens, there is a trend of superiority emerging for the “concomitant” therapy over the “sequential” regimen. “Hybrid” therapy, a combination of sequential and concomitant find more therapy, has also shown advantage over sequential therapy.

Levofloxacin-based therapies appear to be useful and versatile in second- and third-line therapies, with interesting results for newer generation quinolones, which may partially overcome antibiotic resistance. Some promising works have been reported for bismuth-based rescue therapy, using individualized therapies upon antimicrobial information, as well as for rifabutin fourth-line therapy. Probiotics appear to have an effect in terms of reducing side effects and improving compliance, but data on improvement of eradication rates remain controversial. A number of interesting articles have Bortezomib cell line been published over the last year assessing many issues around Helicobacter pylori eradication therapy, including the updated European Consensus Guidelines on H. pylori therapy (Maastricht/Florence Consensus Report) [1]. This article

addresses the published literature over the last year pertaining to these topics. These focused this website primarily on assessing the efficacy of standard triple therapy, as well as exploring new first-line treatments, mainly optimized triple therapies and nonbismuth quadruple schemes. There was also progress in investigating antibiotic resistance rates and the rescue therapies required to deal with ensuing treatment failures, especially novel fluoroquinolones. There have also been advances in acid suppression and an evolution in the use of adjuvant therapies, especially probiotic therapies, which were extensively examined. What is without dispute is that the eradication of H. pylori remains a worthwhile goal to alleviate the burden of disease caused by the complications of this infection, including dyspepsia, peptic ulcer disease, and gastric cancer. One particularly interesting paper looked at the role of H. pylori eradication in preventing rebleeding from peptic ulcers and showed virtually no recurrence in patients with complicated ulcers after H.